Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 double-blind placebo-controlled dose-escalation study of adjunctive perampanel in refractory partial seizures
2007-006169-33Phase 3Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- May 2008
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of perampanel in epilepsy and Focal onset seizure (4 arms), sponsored by Eisai Co., Ltd. Primary endpoint: Percent change in 28-day seizure frequency. Started May 2008; status: completed.
02
Drugs
perampanel
03
Conditions
epilepsyFocal onset seizure
Beyond the preview
Go deeper on 2007-006169-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006169-33.